Ocular Therapeutix (OCUL) EPS (Weighted Average and Diluted) (2018 - 2025)
Historic EPS (Weighted Average and Diluted) for Ocular Therapeutix (OCUL) over the last 8 years, with Q4 2025 value amounting to -$0.27.
- Ocular Therapeutix's EPS (Weighted Average and Diluted) rose 357.14% to -$0.27 in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.42, marking a year-over-year decrease of 1360.0%. This contributed to the annual value of -$1.42 for FY2025, which is 1639.34% down from last year.
- As of Q4 2025, Ocular Therapeutix's EPS (Weighted Average and Diluted) stood at -$0.27, which was up 357.14% from -$0.38 recorded in Q3 2025.
- In the past 5 years, Ocular Therapeutix's EPS (Weighted Average and Diluted) ranged from a high of -$0.22 in Q1 2022 and a low of -$0.49 during Q1 2024
- For the 5-year period, Ocular Therapeutix's EPS (Weighted Average and Diluted) averaged around -$0.29, with its median value being -$0.26 (2021).
- In the last 5 years, Ocular Therapeutix's EPS (Weighted Average and Diluted) surged by 8283.58% in 2021 and then crashed by 7727.27% in 2023.
- Quarter analysis of 5 years shows Ocular Therapeutix's EPS (Weighted Average and Diluted) stood at -$0.23 in 2021, then dropped by 4.35% to -$0.24 in 2022, then dropped by 4.17% to -$0.25 in 2023, then dropped by 12.0% to -$0.28 in 2024, then increased by 3.57% to -$0.27 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.27 for Q4 2025, versus -$0.38 for Q3 2025 and -$0.39 for Q2 2025.